autologous genetically modified t cells, ny-eso-1c259 t
Cell therapyexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01352286)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous genetically modified t cells, ny-eso-1c259 t
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03399448 | Phase 1 | Sep 5, 2018 | University of Pennsylvania |
| NCT02992743 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Adaptimmune, Cornell University |
| NCT02588612 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Adaptimmune, University of Texas at Houston |
| NCT01352286 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2011 | Adaptimmune, University of Maryland |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adaptimmune | For profit | 3 | 3 | 1 | 2011 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1